Overview

* Ashland fiscal Q4 revenue down 8% yr/yr, missing analyst expectations

* Adjusted EBITDA for fiscal Q4 beats analyst estimates, reflecting operational efficiency

* Company received $103 mln tax refund, strengthening financial position

Outlook

* Ashland expects fiscal 2026 sales between $1,835 mln and $1,905 mln

* Company forecasts adjusted EBITDA of $400 mln to $430 mln for fiscal 2026

* Ashland anticipates double-digit-plus growth in adjusted EPS excluding intangibles amortization

Result Drivers

* PORTFOLIO OPTIMIZATION - Reduced sales by $38 mln due to divestitures and product line exits, impacting overall revenue

* LIFE SCIENCES DEMAND - Stable demand in pharmaceuticals driven by innovation and high-value excipients

* PERSONAL CARE GROWTH - Strong growth due to strategic investments and innovation across end markets

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Miss $478 mln $480.55

Revenue mln (7

Analysts

)

Q4 EPS $0.71

Q4 Net $32 mln

Income

Q4 Beat $119 mln $118.26

Adjusted mln (10

EBITDA Analysts

)

Q4 Free $52 mln

Cash

Flow

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)